<DOC>
	<DOCNO>NCT00656981</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety drospirenone 3 mg/ethinyl estradiol 0.02 mg ( DRSP/EE ) comparison placebo female subject moderate acne vulgaris 6 treatment cycle</brief_summary>
	<brief_title>Evaluate Safety Efficacy Oral Contraceptive ( OC ) Preparation Versus Placebo 6 Treatment Cycles Women With Moderate Acne</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Female age 1445 , 10 100 comedo ( noninflammatory lesion ) , 10 50 inflammatory lesion ( papule pustule ) , 35 nodule ( &lt; 5mm ) face ) . Standard contraindication use combined oral contraceptive ( class label ) plus Subjects acne atopia , comedonal acne acne conglobate , sandpaper acne acne multiple large node , cyst , fistular comedo , abscessing fistular duct Use comedogenic cover cream , comedogenic sunscreen , sex hormone preparation antiacne therapy ( eg , light therapy , oleic acid , chemical peeling , mechanical extraction comedo ) Acne therapy sex hormone preparation give 3 month longer prove unsuccessful Preparations acneinducing effect , eg , iodinate bromate drug , tuberculostatics , lithium , Vitamin B1 , B6 , B12 , D3 , corticoid , ACTH , anabolics , quinine , disulfiram , methoxypsoralen , phenobarbital , phenytoin , trimethadione , thyroid depressant , certain oily cosmetic</criteria>
	<gender>Female</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Moderate Acne Vulgaris</keyword>
	<keyword>Acne</keyword>
</DOC>